



## **ASX ANNOUNCEMENT**

# **Lumos Diagnostics Expands Agreement with WellStreet Urgent Care to 43 Locations**

### **Key Highlights**

- **Lumos expands agreement with WellStreet to rollout FebriDx® usage across an additional 43 locations**
- **Successful rollout in this phase will potentially support adoption of FebriDx® usage across all 163 WellStreet locations**
- **The WellStreet urgent care network represents approximately 1.1 million acute respiratory presentations per annum**
- **Increased volume and improved payor visibility from the expanded program should strengthen future contracting discussions with new health care providers**

**MELBOURNE, Australia (14 April 2026)** – Lumos Diagnostics Holdings Ltd (ASX: LDX, “Lumos” or the “Company”), a leader in rapid, point-of-care diagnostic technologies, today received confirmation that WellStreet Urgent Care (“WellStreet”) will expand its FebriDx® program from a single initial site to a further 43 of its urgent care locations.

On 16 October 2025, Lumos announced that it had entered into an agreement with WellStreet Urgent Care (“WellStreet”) to advance testing and reimbursement pathways for FebriDx® through WellStreet’s joint venture with Piedmont Healthcare in Atlanta, Georgia. The Piedmont location handles approximately 50 patients per day presenting predominantly with acute respiratory infections (ARI), providing volume and operational insight.

Following the success of this initial program and supported by the recent granting of CLIA waiver for FebriDx® by the US Food and Drug Administration (FDA) on 27 March 2026, the parties have agreed to expand this program. The next phase will comprise an expanded rollout across an additional 43 sites over the next two months, drawn from WellStreet’s network of 163 urgent care locations throughout the US.

This expansion will comprise additional sites in the Fayetteville District (8 locations), a second Georgia District in the East (7 locations) and the entire Michigan market (28 locations). Once this phase is completed, the Company’s expectation is that WellStreet will launch FebriDx in the remaining WellStreet Urgent Care locations over the next 6-12 months.

Under a standing order protocol implemented by WellStreet, as part of the expanded program, FebriDx® will be offered to every patient presenting with ARI symptoms. Test results will be available to the provider prior to entering the examination room, enabling faster clinical decision-making and more timely diagnosis and treatment of patients.

*"At WellStreet, we are always looking for ways to put better information in the hands of our providers at the moment it matters most," said Dr. Michael Duchynski, Chief Operating Officer and Chief Medical Officer at WellStreet Urgent Care. "Expanding FebriDx® across our network is a natural next step — it supports our commitment to evidence-based care and helps ensure every patient gets the right treatment, faster."*

*"The integration of FebriDx® into our clinical workflow reflects our ongoing commitment to innovation in urgent care," said Brian S. Bobb, MD, Senior Medical Officer and SVP at WellStreet Urgent Care. "Point-of-care diagnostics like FebriDx® give our providers actionable data before they even enter the exam room — that kind of precision directly supports better patient outcomes and antibiotic stewardship. As we scale this program across our network, we're setting a new standard for how respiratory illness is evaluated and treated in the urgent care setting."*

**Doug Ward, CEO of Lumos Diagnostics said:** *"The expansion into the additional WellStreet locations represents an important next step for FebriDx®, by increasing test volume across a broader geographic footprint, improving payor visibility, and strengthening our position in future contracting discussions with potential new providers."*

**-Ends-**

***This announcement has been approved by the Lumos Disclosure Committee.***

### **About WellStreet Urgent Care**

*Founded in 2011 in Atlanta, Georgia, WellStreet Urgent Care began as an independent operator and quickly expanded to a network of seven locations within its first year. In 2014, WellStreet pioneered its partnership model, joining forces with Piedmont Healthcare to extend the Piedmont Urgent Care brand across North Georgia. This model continued to evolve in 2019 when WellStreet partnered with Beaumont, now Corewell Health, to operate a network of urgent care centers in Southeastern Michigan. Further expanding its reach, WellStreet entered into new partnerships in early 2023 with University Hospitals and Prisma Health, strengthening its presence in the urgent care industry. Despite rapid growth, WellStreet remains dedicated to delivering best-in-class quality and an exceptional patient experience, ensuring uncompromising care for each patient, one at a time. WellStreet is committed to adapting and innovating to meet the healthcare needs of tomorrow, always prioritizing the well-being of those it serves.*

*For more information visit [wellstreet.com](https://www.wellstreet.com).*

## **About FebriDx**

FebriDx® is a rapid, point-of-care test that helps healthcare professionals differentiate between bacterial and non-bacterial respiratory infections in around 10 minutes, supporting more informed clinical decision-making and potentially reducing unnecessary antibiotic prescribing.

## **About Lumos Diagnostics,**

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com).

## **Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

## **Media Contacts:**

Tom Trezona – Australia  
H^CK Acting Managing Director  
[tom@hck.digital](mailto:tom@hck.digital)  
+61 411 235 692

## **Investor Contact:**

George Kopsiaftis  
IR Specialist, IR Department  
[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)  
+61 409 392 687

## **Company Registered Office:**

Lumos Diagnostics Holdings Ltd  
Suite 2, Level 11  
385 Bourke Street  
Melbourne VIC 3000  
[info@lumosdiagnostics.com](mailto:info@lumosdiagnostics.com)  
+61 3 9087 1598